About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Anticancer Drug - Larotrectinib Shows 93 Percent Success Rate

by Rishika Gupta on April 2, 2018 at 3:46 PM
Font : A-A+

New Anticancer Drug - Larotrectinib Shows 93 Percent Success Rate

Larotrectinib could be the first drug that targets a fused gene which is found in a lot of cancers, finds a new study. This drug has earned the FDA breakthrough therapy designation for being 93 percent effective in pediatric patients.

The findings of this study are published in the Lancet Oncology journal.

Advertisement


Most cancer drugs are targeted to specific organs or locations in the body. Larotrectinib is the first cancer drug to receive FDA breakthrough therapy designation for patients with a specific fusion of two genes in the cancer cell, no matter what cancer type.

"In some cancers, a part of the TRK gene has become attached to another gene, which is called a fusion. When this occurs, it leads to the TRK gene being turned on when it's not supposed to be, and that causes the cells to grow uncontrollably. What's unique about the drug is it is very selective; it only blocks TRK receptors," said lead author Dr. Ted Laetsch, Assistant Professor of Pediatrics and with the Harold C. Simmons Comprehensive Cancer Center.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Cochlear Implants may Consequently Drive Hearing Loss
E-cigarettes Use Linked to Erectile Dysfunction
Memory Loss - Can it be Recovered?
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Signature Drug Toxicity Drugs Banned in India Neutropenic Sepsis 

Recommended Reading
Pediatric Cancer Risk Higher in Children Born Post-Fertility Treatment
Fertility treatments increases risk of neoplasms like leukemia, brain and spinal cord tumors, ......
Two Investigational Antitumor Agents Efficacious Against a Rare Pediatric Cancer
Malignant peripheral nerve sheath tumor (MPNST) is a rare pediatric cancer and is resistant to ......
Genomic Analysis can Indicate Precision Therapies for Pediatric Cancer
Analyzing genomic alterations can underscore the need for precision therapies to treat pediatric ......
Novel Program to Educate Pediatric Cancer Survivors and Families
An effort by Rutgers Cancer Institute of New Jersey to educate pediatric cancer survivors is ......
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....
Neutropenic Sepsis
Neutropenic sepsis is a potentially life-threatening condition when a patient with low neutrophil co...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use